Aclaris Phase 2 ADMIRATION Trial Of Anti-TSLP Antibody Bosakitug In Atopic Dermatitis Misses Primary Endpoint Of EASI Percent Change At Week 24, Secondary Endpoints Also Not Met

Benzinga
Open on Benzinga